Ralliant (NYSE:RAL) Director Purchases $99,828.00 in Stock

Ralliant Corporation (NYSE:RAL) Director Kate Mitchell purchased 2,350 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was bought at an average cost of $42.48 per share, with a total value of $99,828.00. Following the completion of the acquisition, the director directly owned 8,411 shares of the company’s stock, valued at approximately $357,299.28. This trade represents a 38.77% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Ralliant Stock Performance

NYSE:RAL opened at $44.03 on Friday. The business’s fifty day moving average is $50.79 and its 200 day moving average is $46.56. The firm has a market cap of $4.97 billion and a price-to-earnings ratio of 22.46. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $57.02.

Ralliant (NYSE:RAL) last posted its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. The firm’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be paid a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a yield of 0.5%. Ralliant’s dividend payout ratio is currently 10.20%.

Key Headlines Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Directors/insiders bought stock this week (Kate Mitchell bought 2,350 shares at ~$42.48; Anelise Angelino Sacks bought ~2,000 shares), a signal often read as confidence in the company and a near‑term support for the share price. InsiderTrades: Kate Mitchell Acquires 2,350 Shares The Motley Fool: Director Scoops Up 2,000 Shares
• Neutral Sentiment: Recent quarterly results beat consensus (EPS and revenue) and the company provided Q1 and FY 2026 guidance — fundamentals remain mixed and will be watched closely but are not a new surprise. MarketBeat: Ralliant Earnings & Guidance
• Negative Sentiment: Multiple law firms have publicly opened or promoted investigations into possible securities‑law violations tied to Ralliant (Kaplan Fox, Kirby McInerney, Kessler Topaz, Block & Leviton and others). Those actions increase litigation and regulatory risk and can pressure the stock as legal costs, disclosures and management distraction unfold. Globe and Mail: Kaplan Fox Alert GlobeNewswire: Kirby McInerney Alert
• Negative Sentiment: Ongoing negative analyst moves, higher short interest and prior material non‑cash impairment/guidance reductions (reported earlier) raise downside risk and intraday volatility — these factors can offset positive insider signals and lead to further selling on adverse updates. Kessler Topaz PR Business Insider: Block & Leviton Alert

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on RAL shares. Truist Financial lowered their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Vertical Research upgraded Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Friday, February 6th. Zacks Research cut Ralliant from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Barclays cut their price objective on Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Ralliant in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ralliant has an average rating of “Hold” and an average target price of $50.50.

Hedge Funds Weigh In On Ralliant

Institutional investors have recently modified their holdings of the company. Danske Bank A S bought a new stake in Ralliant in the 4th quarter worth approximately $25,000. Westfuller Advisors LLC bought a new stake in shares of Ralliant in the 3rd quarter worth approximately $26,000. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant in the 4th quarter valued at $26,000. Allworth Financial LP grew its holdings in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. Finally, Palisade Asset Management LLC purchased a new position in Ralliant in the 3rd quarter worth $26,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.